362 related articles for article (PubMed ID: 19489750)
1. Is withdrawal hyperalgesia in morphine-dependent mice a direct effect of a low concentration of the residual drug?
Rubovitch V; Pick CG; Sarne Y
Addict Biol; 2009 Sep; 14(4):438-46. PubMed ID: 19489750
[TBL] [Abstract][Full Text] [Related]
2. Ketorolac prevents recurrent withdrawal induced hyperalgesia but does not inhibit tolerance to spinal morphine in the rat.
Dunbar SA; Karamian I; Zhang J
Eur J Pain; 2007 Jan; 11(1):1-6. PubMed ID: 16448827
[TBL] [Abstract][Full Text] [Related]
3. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
4. Mechanical allodynia and thermal hyperalgesia upon acute opioid withdrawal in the neonatal rat.
Sweitzer SM; Allen CP; Zissen MH; Kendig JJ
Pain; 2004 Jul; 110(1-2):269-80. PubMed ID: 15275777
[TBL] [Abstract][Full Text] [Related]
5. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
Juni A; Klein G; Kest B
Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
7. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
8. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.
Pałucha-Poniewiera A; Novák K; Pilc A
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1454-7. PubMed ID: 19660510
[TBL] [Abstract][Full Text] [Related]
9. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
10. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
[TBL] [Abstract][Full Text] [Related]
11. Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms.
Pałucha A; Brański P; Pilc A
Pol J Pharmacol; 2004; 56(6):863-6. PubMed ID: 15662102
[TBL] [Abstract][Full Text] [Related]
12. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
Windh RT; Little PJ; Kuhn CM
J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
[TBL] [Abstract][Full Text] [Related]
13. Central administration of selective melanocortin 4 receptor antagonist HS014 prevents morphine tolerance and withdrawal hyperalgesia.
Kalange AS; Kokare DM; Singru PS; Upadhya MA; Chopde CT; Subhedar NK
Brain Res; 2007 Nov; 1181():10-20. PubMed ID: 17915196
[TBL] [Abstract][Full Text] [Related]
14. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Cichewicz DL; Welch SP
J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
16. Analgesic activity and pharmacological characterization of N-[1-phenylpyrazol-3-yl]-N-[1-(2-phenethyl)-4-piperidyl] propenamide, a new opioid agonist acting peripherally.
Goicoechea C; Sánchez E; Cano C; Jagerovic N; Martín MI
Eur J Pharmacol; 2008 Oct; 595(1-3):22-9. PubMed ID: 18706410
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of dichloromethane fraction from the Areca catechu nut on naloxone-precipitated morphine withdrawal in mice.
Kumarnsit E; Keawpradub N; Vongvatcharanon U; Sawangjaroen K; Govitrapong P
Fitoterapia; 2005 Sep; 76(6):534-9. PubMed ID: 15993008
[TBL] [Abstract][Full Text] [Related]
18. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
19. Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal.
Hodgson SR; Hofford RS; Norris CJ; Eitan S
Behav Pharmacol; 2008 Dec; 19(8):805-11. PubMed ID: 19020415
[TBL] [Abstract][Full Text] [Related]
20. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration.
Pinelli A; Cighetti G; Trivulzio S
Fundam Clin Pharmacol; 2008 Aug; 22(4):439-45. PubMed ID: 18705754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
